Merck Commits Billions to U.S. Manufacturing to Avoid 100% Tariffs

Merck has committed billions toward expanding its manufacturing footprint in the United States to secure exemptions from proposed 100% tariffs on branded drugs. The pledge covers new plant development and upgrades at existing sites, targeting increased capacity for both small-molecule and biologic medicines.

The administration’s tariff proposal — imposing a full levy on imported branded medications if not domestically produced or price-cut — has spurred Merck to fast-track project approvals, boost inventory reserves and explore direct-to-consumer channels. Industry-wide delays in enforcement for investing companies offer a grace period for Merck to implement its expansion plans.

Companies investing in U.S. production enjoy delayed tariff enforcement, motivating Merck to accelerate capital allocation over the next five years. This timeframe is expected to see prioritization of research and development infrastructure, with potential new facilities slated for biologics manufacturing and advanced therapy production.